Edwards Lifesciences Corporation $EW Shares Sold by Diversify Advisory Services LLC

Diversify Advisory Services LLC lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 24.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 21,229 shares of the medical research company’s stock after selling 6,719 shares during the quarter. Diversify Advisory Services LLC’s holdings in Edwards Lifesciences were worth $1,763,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Level Four Advisory Services LLC raised its stake in shares of Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after purchasing an additional 119 shares during the last quarter. Colonial Trust Co SC boosted its position in Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after buying an additional 120 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after buying an additional 130 shares during the period. Howard Capital Management Inc. increased its holdings in Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after buying an additional 132 shares during the period. Finally, Empirical Finance LLC raised its position in Edwards Lifesciences by 0.6% during the 2nd quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after buying an additional 134 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EW. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Evercore reaffirmed an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. This represents a 53.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 71,444 shares of company stock valued at $6,035,269. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $84.21 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The stock has a market capitalization of $48.91 billion, a price-to-earnings ratio of 46.02, a PEG ratio of 2.13 and a beta of 0.93. The firm’s 50 day simple moving average is $82.51 and its 200-day simple moving average is $81.49. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.